Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cybin Inc. CYBN NYSE

NYSE • Healthcare • Biotechnology • CA • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Cybin Inc. (CYBN) is a Biotechnology company in the Healthcare sector, currently trading at $8.28. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Net income is $113M (loss), growing at -32%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $237M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.75 (strong liquidity). Debt-to-assets is 0%. Total assets: $259M.

Analyst outlook: 4 / 4 analysts rate CYBN as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

CYBN SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CYBN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
CYBN: +0%/yr revenue is, -32%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet CYBN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 7.75 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
CYBN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 4 / 4 analysts rate CYBN as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range4.81-10.7199
Volume716.53K
Avg Volume (30D)874.38K
Market Cap$413.02M
Beta (1Y)0.79
Share Statistics
EPS (TTM)-0.61
Shares Outstanding$185.43M
IPO Date2019-09-13
Employees50
CEOEric So
Financial Highlights & Ratios
EBITDA$-142.67M
Net Income$-113.14M
Operating Income$-143.15M
Total Cash$135.02M
Net Debt$-135.02M
Total Assets$258.62M
Price / Earnings (P/E)-13.6
Analyst Forecast
Rating ConsensusBuy
Analysts Covering4
Buy 100% Hold 0% Sell 0%
Company Info
CountryCA
ExchangeNYSE
CurrencyUSD
ISINCA23256X4075

Price Chart

Track all markets on TradingView
CYBN
Cybin Inc. ↗  ·  NYSE
Healthcare • Biotechnology
4.81 52WK RANGE 10.72

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 MNMD
MNMD
Mind Medicine (MindMed) Inc.
$20.69
+0.44%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
 GHRS
GHRS
GH Research PLC
$17.00
+1.37%
 ATAI
ATAI
Atai Life Sciences N.V.
$4.00
+3.90%
 IMMX
IMMX
Immix Biopharma, Inc.
$10.04
+1.93%
 ITOS
ITOS
iTeos Therapeutics, Inc.
$10.15
+0.20%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message